CHGCY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 34.69% compared to Chugai Pharmaceutical's net margin of -107.23%. Chugai Pharmaceutical's return on equity of 22.92% beat Healios KK's return on equity of -137.21%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical is more attractive than Healios KK.

Chugai Pharmaceutical has a beta of 0.575, which suggesting that the stock is 42.489% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Chugai Pharmaceutical has a quarterly dividend of $0.14 per share corresponding to a yield of 1.28%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 40.43% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $2.1B, which are larger than Healios KK quarterly revenues of $3.2M. Chugai Pharmaceutical's net income of $737.2M is higher than Healios KK's net income of -$3.4M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 27.29x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 9.28x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 34.69% compared to Chugai Pharmaceutical's net margin of -5.57%. Chugai Pharmaceutical's return on equity of 22.92% beat PeptiDream's return on equity of 34.66%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than PeptiDream, analysts believe Chugai Pharmaceutical is more attractive than PeptiDream.

Chugai Pharmaceutical has a beta of 0.575, which suggesting that the stock is 42.489% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

Chugai Pharmaceutical has a quarterly dividend of $0.14 per share corresponding to a yield of 1.28%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 40.43% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $2.1B, which are larger than PeptiDream quarterly revenues of $36.8M. Chugai Pharmaceutical's net income of $737.2M is higher than PeptiDream's net income of -$2.1M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 27.29x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 9.28x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 34.69% compared to Chugai Pharmaceutical's net margin of 12.96%. Chugai Pharmaceutical's return on equity of 22.92% beat Nxera Pharma's return on equity of -5.58%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Chugai Pharmaceutical is more attractive than Nxera Pharma.

Chugai Pharmaceutical has a beta of 0.575, which suggesting that the stock is 42.489% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

Chugai Pharmaceutical has a quarterly dividend of $0.14 per share corresponding to a yield of 1.28%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 40.43% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $2.1B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Chugai Pharmaceutical's net income of $737.2M is higher than Nxera Pharma's net income of $8.1M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 27.29x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 9.28x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 34.69% compared to Chugai Pharmaceutical's net margin of 7.83%. Chugai Pharmaceutical's return on equity of 22.92% beat Takeda Pharmaceutical's return on equity of 4.01%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 22.35%. Given that Takeda Pharmaceutical has higher upside potential than Chugai Pharmaceutical, analysts believe Takeda Pharmaceutical is more attractive than Chugai Pharmaceutical.

Chugai Pharmaceutical has a beta of 0.575, which suggesting that the stock is 42.489% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

Chugai Pharmaceutical has a quarterly dividend of $0.14 per share corresponding to a yield of 1.28%. Takeda Pharmaceutical offers a yield of 4.72% to investors and pays a quarterly dividend of $0.33 per share. Chugai Pharmaceutical pays 40.43% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Chugai Pharmaceutical quarterly revenues are $2.1B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Chugai Pharmaceutical's net income of $737.2M is higher than Takeda Pharmaceutical's net income of $619.7M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 27.29x while Takeda Pharmaceutical's PE ratio is 21.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 9.28x versus 1.38x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.